Your browser is no longer supported. Please, upgrade your browser.
Settings
KITE Kite Pharma, Inc. daily Stock Chart
KITE [NASD]
Kite Pharma, Inc.
Index- P/E- EPS (ttm)-6.27 Insider Own1.80% Shs Outstand57.94M Perf Week3.39%
Market Cap4.24B Forward P/E- EPS next Y-6.75 Insider Trans-32.72% Shs Float51.31M Perf Month-11.53%
Income-313.60M PEG- EPS next Q-1.91 Inst Own90.40% Short Float18.83% Perf Quarter28.65%
Sales26.90M P/S157.47 EPS this Y-134.30% Inst Trans7.44% Short Ratio5.33 Perf Half Y43.63%
Book/sh15.05 P/B4.86 EPS next Y20.70% ROA-47.00% Target Price84.92 Perf Year52.92%
Cash/sh13.88 P/C5.27 EPS next 5Y- ROE-55.80% 52W Range39.82 - 88.58 Perf YTD63.05%
Dividend- P/FCF- EPS past 5Y- ROI-63.20% 52W High-17.46% Beta-
Dividend %- Quick Ratio10.30 Sales past 5Y- Gross Margin- 52W Low83.60% ATR3.22
Employees447 Current Ratio10.30 Sales Q/Q92.20% Oper. Margin- RSI (14)44.75 Volatility4.17% 4.26%
OptionableYes Debt/Eq0.00 EPS Q/Q-93.90% Profit Margin- Rel Volume0.65 Prev Close74.91
ShortableYes LT Debt/Eq0.00 EarningsMay 08 BMO Payout- Avg Volume1.81M Price73.11
Recom2.30 SMA20-3.56% SMA50-6.24% SMA20021.62% Volume1,183,081 Change-2.40%
May-09-17Reiterated FBR & Co. Outperform $90 → $91
May-09-17Downgrade Wedbush Neutral → Underperform $60 → $54
May-08-17Downgrade Raymond James Outperform → Mkt Perform
Mar-13-17Downgrade Standpoint Research Buy → Hold
Mar-06-17Reiterated RBC Capital Mkts Outperform $85 → $95
Mar-03-17Downgrade Stifel Buy → Hold $74
Mar-02-17Downgrade Citigroup Buy → Neutral
Mar-01-17Reiterated Maxim Group Buy $77 → $84
Feb-28-17Reiterated H.C. Wainwright Buy $78 → $85
Feb-22-17Initiated Wells Fargo Market Perform
Feb-02-17Initiated Wedbush Neutral $46
Jan-04-17Initiated ROTH Capital Buy $68
Nov-21-16Initiated H.C. Wainwright Buy $78
Aug-09-16Reiterated Maxim Group Buy $87 → $77
Jul-13-16Reiterated Stifel Buy $63 → $74
Jun-02-16Initiated Raymond James Outperform $61
May-10-16Reiterated Mizuho Buy $90 → $80
Feb-25-16Initiated Citigroup Buy $67
Feb-02-16Initiated RBC Capital Mkts Outperform $85
Jan-19-16Upgrade FBR Capital Mkt Perform → Outperform $75
May-26-17 10:47AM  Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel Business Wire
May-25-17 04:21PM  I Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug Motley Fool
May-17-17 05:10PM  Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting TheStreet.com -6.69%
05:05PM  Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting Business Wire
May-15-17 09:00PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Kite Pharma Inc. Business Wire
03:16PM  This Hedge Funds Picks Returned 52% in Q1 And Youve Never Heard of It Insider Monkey
May-14-17 10:20AM  Insider Buying Soars as Q1 Earnings Wind Up: Tempur Sealy, Apollo Global, Revlon, Kite Pharma and More 24/7 Wall St.
May-12-17 11:15PM  Edited Transcript of KITE earnings conference call or presentation 8-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-11-17 07:03PM  Kite Pharma, Inc. Value Analysis (NASDAQ:KITE) : May 11, 2017 Capital Cube
02:38PM  Insiders Are Loading Up on Kite Pharma, Cliffs Natural Resources and More TheStreet.com
May-10-17 08:30AM  Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death Zacks
May-09-17 03:40PM  CYRX: Biopharma, Clinical Trial Growth, Fuels Another Record Quarter Zacks Small Cap Research
08:58AM  Kite Pharma, Inc. breached its 50 day moving average in a Bearish Manner : KITE-US : May 9, 2017 Capital Cube
08:00AM  Today's Research Reports on Trending Tickers: Celgene and Kite Pharma Accesswire
07:43AM  Kite Pharma (KITE) Posts Q1 Loss, Reveals CAR-T Patient Death Zacks
May-08-17 09:06PM  Edited Transcript of KITE earnings conference call or presentation 8-May-17 12:30pm GMT Thomson Reuters StreetEvents -13.19%
05:51PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Kite Pharma, Inc. Business Wire
05:17PM  KITE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Kite Pharma, Inc. To Contact The Firm Business Wire
04:36PM  These Drugmakers Plunged On Consensus-Lagging Q1 Sales, Losses Investor's Business Daily
03:00PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Kite Pharma, Inc. Business Wire
01:29PM  KITE Plunges, Take Sector With It Investopedia
01:26PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Kite Pharma, Inc. (KITE) PR Newswire
01:07PM  Kite Pharma Breaks Down & Could Close the Gap Investopedia
12:57PM  Here's What's Dragging Kite Pharma Inc. Down Today Motley Fool
12:14PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kite Pharma, Inc. - KITE PR Newswire
11:46AM  Here's Why Kite Pharma (KITE) Stock Is Plummeting Today Zacks
11:31AM  Analyst: Kite Pharma's CAR-T Patient Death, Stock Selloff Is A Buying Opportunity Benzinga
11:00AM  Biotech And Pharma Industry And Stock News Investor's Business Daily
10:06AM  Kite Pharma Discloses CAR-T Patient Death, Rattling Investors TheStreet.com
09:21AM  Kite Pharma (KITE) Q1 Loss Wider than Expected, Sales Miss Zacks
08:06AM  Kite Pharma reports 1Q loss Associated Press
08:00AM  Kite Reports First Quarter Financial Results Business Wire
07:15AM  Investor Network: Kite Pharma, Inc. to Host Earnings Call Accesswire
May-03-17 03:36PM  Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards? Zacks
May-01-17 08:30AM  Kite to Report First Quarter 2017 Financial Results on May 8, 2017 Business Wire
Apr-28-17 04:54PM  Insiders Roundup: Peabody Energy, Liberty SiriusXM GuruFocus.com
Apr-19-17 12:46PM  If You're in Your 30s, You Should Consider Buying These Stocks Motley Fool
Apr-18-17 07:05AM  Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps TheStreet.com
Apr-12-17 06:03AM  The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17) TheStreet.com
Apr-11-17 06:53PM  Cramer's charts show these biotechs ignoring their 'polit... CNBC Videos
Apr-06-17 04:20PM  The First CAR-T Drugs Have Left the Gate Motley Fool
08:30AM  Kite Wins Clinical Trial Result of the Year for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards Business Wire
Apr-05-17 12:20PM  Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait TheStreet.com
08:59AM  Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug Zacks
Apr-04-17 03:35PM  Kite Presents Promising Preclinical Data from KITE-585, a Fully Human Anti-BCMA CAR T-Cell Product Candidate at the 2017 American Association of Cancer Research (AACR) Annual Meeting Business Wire
08:30AM  Kite Highlights Publication on Breakthrough in Generating Fully Functioning T Cells from Hematopoietic Precursor Cells by Leading Researchers at the University of California, Los Angeles (UCLA) Business Wire
Apr-03-17 04:19PM  Snap Started At Hold, Kite Pharma Can't Stay Aloft, Accenture Cut Investor's Business Daily
09:29AM  Biotech Movers: Novocure, United Therapeutics, Kite Pharma
07:06AM  Kite Pharma Completes Filing for CAR-T Therapy with FDA Zacks
Apr-02-17 04:04PM  Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting Business Wire
Mar-31-17 03:15PM  Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL) Business Wire
Mar-30-17 10:50AM  Novartis' CTL109 BLA Gets Priority Review Status from FDA
10:50AM  Novartis' CTL109 BLA Gets Priority Review Status from FDA Investopedia
09:22AM  Amgen's Blincyto sBLA Secures FDA Priority Review at Investopedia
09:08AM  Novartis' Leukemia Drug Secures Priority Review at Investopedia
08:30AM  Kite to Present Two Plenary Presentations from the ZUMA-1 Pivotal Trial of Axicabtagene Ciloleucel at the 2017 American Association of Cancer Research Annual Meeting Business Wire
Mar-29-17 06:15PM  Novartis Makes Plans For Its Cancer-Killing T Cells at Forbes
08:42AM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. Kite Pharma at Motley Fool
Mar-20-17 09:00AM  CYRX: Growth in Clinical Trial Customers Pushing Revenue To Record Heights
Mar-17-17 08:23AM  Why Kite Pharma Stock Is Already Up 62% This Year at Motley Fool
Mar-16-17 04:37PM  KITE PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
08:30AM  Kite Announces Appointment of Renowned Cancer Researcher, Owen N. Witte, M.D., to its Board of Directors Business Wire
Mar-15-17 08:03AM  3 Reasons Why Gilead Sciences Will Buy Incyte -- and 1 Reason Why It Won't at Motley Fool
Mar-14-17 04:14PM  Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Business Wire
10:55AM  Gilead Looking To Buy Incyte? It Makes Sense
06:02AM  Rev's Forum: Don't Underestimate the Power of a Plodding Market
Mar-13-17 05:14PM  Market Takes 'National Napping Day' Seriously
11:16AM  Kite Pharma downgraded by Standpoint Research
10:11AM  Top Stocks That Are Already Crushing the Market in 2017 at Motley Fool
Mar-10-17 01:04PM  KITE PHARMA, INC. Financials
07:41AM  3 Stocks Begging for a Buyout at Motley Fool
Mar-09-17 04:03PM  Will Pfizer Take On Celgene, Other Rivals With Leukemia Drug? +7.93%
02:35PM  Will Merck, Glaxo Undercut Gilead's Next 'Mount Everest' Drug?
01:46PM  Shark Bites: Market Needs a Bounce in Its Step
10:47AM  Market Set Up for Oversold Bounce
Mar-08-17 11:19AM  Watching Financials and Biotech in This Tepid Market
08:30AM  Kite Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Mar-07-17 01:55PM  Harry Boxers six biotechnology stocks to watch at MarketWatch
01:14PM  Inside the Head of a Trader: Tuesday Morning With James 'Rev Shark' Deporre
10:38AM  Woe to Those Who Are Trapped When the Daily Pattern Is Broken
09:41AM  What Caused Kite Pharma's Shares to Soar 34.6% in February at Motley Fool
Mar-06-17 05:17PM  KITE PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
01:10PM  RBC Hints At Potential M&A For Kite Pharma
09:02AM  Hot IPO Snap Rated Sell, Netflix A Buy, HP Upgraded
08:30AM  Kite to Present at March 2017 Investor Conferences Business Wire
Mar-05-17 04:00PM  Richard L. Wang Named Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd., a Joint Venture to Lead Development of Axicabtagene Ciloleucel and Other Engineered T-Cell Therapies for Treatment of Cancers in China Business Wire
Mar-03-17 02:28PM  Stifel Cuts Kite Pharma To Hold On Valuation, Complex Drug Launch at Barrons.com
09:09AM  Four biotech stocks surging on optimism about drug trials, product launches at MarketWatch
Mar-02-17 03:34PM  Biotechs Breaking Out On Drug Development News at Forbes -5.68%
02:00PM  With Big Hopes for Cancer Drug, Kite Raising $350M
09:43AM  Kite Pharma, Inc. :KITE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017
09:23AM  Kite Announces Pricing of Public Offering of Common Stock Business Wire
08:15AM  Blog Coverage Kite Pharma CAR-T Cancer Therapy Demonstrate Positive Results in B-cell non-Hodgkin Lymphoma Accesswire
07:20AM  Kite Pharma launches public stock sale following recent price surge at MarketWatch
06:40AM  Kite Announces Commencement of Public Offering of Common Stock Business Wire
Mar-01-17 05:15PM  Why Kite Pharma's Shares Skyrocketed 12.5% Higher Today at Motley Fool +12.51%
04:40PM  Vetr Downgrades The High-Flying Kite
09:53AM  Kite Pharma (KITE) Posts Q4 Loss; Up on Positive Cancer Data
09:48AM  Kite Pharma Hits 52-Week High on Positive Trial at Investopedia
07:24AM  Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptor (CAR)-based therapy that is in Phase 2 clinical trials for patients with relapsed or refractory aggressive diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma. The company is also conducting a Phase 2 clinical trial of KTE-C19 on patients with relapsed/refractory mantle cell lymphoma; a Phase 1-2 clinical trial of KTE-C19 on adult patients with relapsed/refractory acute lymphoblastic leukemia; and a Phase 1-2 clinical trial of KTE-C19 in pediatric patients with relapsed/refractory, as well as Phase 1b/2 clinical trial of KTE-C19 in combination with Genentech's atezolizumab in patients with refractory DLBCL. In addition, it engages in developing T cell receptors-based therapies, which targets self-antigens, viral antigens, and neo-antigens. The company has a research collaboration and license agreement with Amgen Inc. to develop and commercialize various CAR-based product candidates; cooperative research and development agreements with the U.S. Department of Health and Human Services; a license agreement with Cabaret Biotech Ltd. and National Institutes of Health; a license and research agreement with Alpine Immune Sciences, Inc.; and a research collaboration and license agreement with Cell Design Labs, Inc. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JENKINSON PAUL LChief Financial OfficerMay 10Buy72.593,000217,7703,000May 10 03:12 PM
JENKINSON PAUL LChief Financial OfficerMay 10Buy72.5745032,6577,480May 10 03:12 PM
Ruchefsky Steven BDirectorMay 09Buy69.501,40097,300225,426May 10 12:52 PM
BONDERMAN DAVIDDirectorMay 09Buy68.9450,0003,446,9982,408,084May 09 06:29 PM
Nussbaum RanDirectorMay 09Buy69.119,832679,4743,520May 11 02:02 PM
Belldegrun ArieChairman, President and CEOMay 09Buy68.5717,0001,165,69085,507May 09 03:37 PM
Chang David DEVP, R&D, Chief Medical Off.May 01Option Exercise6.8920,000137,80070,165May 03 06:06 PM
Kim Helen SusanEVP, Business DevelopmentMay 01Option Exercise53.902,400129,36021,064May 03 06:08 PM
Kim Helen SusanEVP, Business DevelopmentMay 01Sale82.122,400197,08818,664May 03 06:08 PM
Chang David DEVP, R&D, Chief Medical Off.May 01Sale82.0920,0001,641,74450,165May 03 06:06 PM
CHAMPSI FARAHDirectorApr 28Sale82.592,617216,1384,962May 01 06:52 PM
CHAMPSI FARAHDirectorApr 27Sale82.7716,5511,369,9267,579May 01 06:52 PM
CHAMPSI FARAHDirectorApr 26Sale82.7251,3124,244,59724,130Apr 26 05:38 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 25Option Exercise1.3515,00020,250132,795Apr 27 06:49 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 25Sale81.8515,0001,227,690117,795Apr 27 06:49 PM
CHAMPSI FARAHDirectorApr 25Sale82.8046,7833,873,58575,442Apr 26 05:38 PM
CHAMPSI FARAHDirectorApr 24Sale82.3425,8182,125,854122,225Apr 26 05:38 PM
CHAMPSI FARAHDirectorApr 17Sale82.4843,1013,555,028148,043Apr 17 09:24 PM
CHAMPSI FARAHDirectorApr 13Sale82.3972,2755,954,737191,144Apr 17 09:24 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 03Option Exercise1.355,0006,750122,795Apr 04 04:15 PM
Kim Helen SusanEVP, Business DevelopmentApr 03Option Exercise53.902,400129,36021,064Apr 04 04:16 PM
Chang David DEVP, R&D, Chief Medical Off.Apr 03Option Exercise6.8920,000137,80070,165Apr 04 04:17 PM
Chang David DEVP, R&D, Chief Medical Off.Apr 03Sale81.5420,0001,630,86650,165Apr 04 04:17 PM
Kim Helen SusanEVP, Business DevelopmentApr 03Sale81.802,400196,32018,664Apr 04 04:16 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 03Sale81.965,000409,798117,795Apr 04 04:15 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 27Option Exercise1.3510,00013,500127,795Mar 28 07:57 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 27Sale77.6710,000776,746117,795Mar 28 07:57 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 09Option Exercise1.3521,11828,509138,913Mar 10 05:25 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 09Sale80.7821,1181,705,929117,795Mar 10 05:25 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 01Option Exercise1.3528,88238,991146,677Mar 01 09:59 PM
Chang David DEVP, R&D, Chief Medical Off.Mar 01Option Exercise6.8960,000413,400110,165Mar 02 06:08 AM
DOUMANI ROYDirectorMar 01Option Exercise1.3550,00067,50075,065Mar 02 06:06 AM
Kim Helen SusanEVP, Business DevelopmentMar 01Option Exercise53.902,400129,36021,064Mar 02 06:05 AM
Wiezorek JeffreySVP Clinical DevelopmentMar 01Option Exercise6.8918,000124,02039,071Mar 02 06:09 AM
Wiezorek JeffreySVP Clinical DevelopmentMar 01Sale75.0118,0001,350,14421,071Mar 02 06:09 AM
Kim Helen SusanEVP, Business DevelopmentMar 01Sale75.432,400181,03918,664Mar 02 06:05 AM
DOUMANI ROYDirectorMar 01Sale76.772,800214,94225,065Mar 02 06:06 AM
DOUMANI ROYDirectorMar 01Sale74.0516,0001,184,873115,017Mar 02 06:06 AM
Chang David DEVP, R&D, Chief Medical Off.Mar 01Sale79.1660,0004,749,44150,165Mar 02 06:08 AM
BUTITTA CYNTHIA MChief Operating OfficerMar 01Sale80.0528,8822,312,004117,795Mar 01 09:59 PM
Kim Helen SusanEVP, Business DevelopmentFeb 28Option Exercise52.2747,9002,503,75666,564Mar 02 06:05 AM
Kim Helen SusanEVP, Business DevelopmentFeb 28Sale67.4047,9003,228,37218,664Mar 02 06:05 AM
BUTITTA CYNTHIA MChief Operating OfficerFeb 27Option Exercise1.3510,00013,500127,795Mar 01 09:59 PM
BUTITTA CYNTHIA MChief Operating OfficerFeb 27Sale54.4210,000544,178117,795Mar 01 09:59 PM
Wiezorek JeffreySVP Clinical DevelopmentFeb 01Option Exercise6.891,50010,33522,195Feb 06 04:36 PM
Wiezorek JeffreySVP Clinical DevelopmentFeb 01Sale51.211,50076,82020,695Feb 06 04:36 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 31Option Exercise1.3510,00013,500127,795Feb 01 07:09 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 31Sale50.5610,000505,562117,795Feb 01 07:09 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 06Option Exercise1.3510,00013,500127,795Jan 10 05:03 PM
Wiezorek JeffreySVP Clinical DevelopmentJan 06Option Exercise6.891,50010,33522,195Jan 10 05:04 PM
Wiezorek JeffreySVP Clinical DevelopmentJan 06Sale50.001,50075,00020,695Jan 10 05:04 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 06Sale50.1310,000501,289117,795Jan 10 05:03 PM
Wiezorek JeffreySVP Clinical DevelopmentDec 20Sale50.8671636,41615,095Dec 22 04:53 PM
Tomasello ShawnChief Commercial OfficerDec 20Sale50.864,901249,26549,635Dec 22 04:52 PM
Kim Helen SusanEVP, Business DevelopmentDec 20Sale50.8693647,6058,064Dec 22 04:51 PM
Chang David DEVP, R&D, Chief Medical Off.Dec 20Sale50.861,78890,93825,123Dec 22 04:50 PM
Belldegrun ArieChairman, President and CEODec 20Sale50.863,493177,65424,707Dec 22 04:47 PM
BUTITTA CYNTHIA MChief Operating OfficerDec 20Sale50.862,482126,23592,995Dec 22 04:48 PM
Wiezorek JeffreySVP Clinical DevelopmentDec 01Option Exercise6.891,50010,33517,311Dec 05 07:03 PM
Wiezorek JeffreySVP Clinical DevelopmentDec 01Sale50.761,50076,13415,811Dec 05 07:03 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 25Option Exercise1.3510,00013,500105,477Nov 29 05:02 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 25Sale50.4010,000504,01595,477Nov 29 05:02 PM
Wiezorek JeffreySVP Clinical DevelopmentNov 10Option Exercise6.891,50010,33517,311Nov 14 06:55 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 10Option Exercise1.3510,00013,500105,477Nov 14 06:57 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 10Sale50.6510,000506,46795,477Nov 14 06:57 PM
Wiezorek JeffreySVP Clinical DevelopmentNov 10Sale50.181,50075,27015,811Nov 14 06:55 PM
Wiezorek JeffreySVP Clinical DevelopmentOct 03Option Exercise6.891,50010,33517,311Oct 05 07:44 PM
Wiezorek JeffreySVP Clinical DevelopmentOct 03Sale54.811,50082,21415,811Oct 05 07:44 PM
BUTITTA CYNTHIA MChief Operating OfficerSep 26Option Exercise1.3510,00013,500105,477Sep 28 05:03 PM
BUTITTA CYNTHIA MChief Operating OfficerSep 26Sale54.1310,000541,30095,477Sep 28 05:03 PM
Wiezorek JeffreySVP Clinical DevelopmentSep 01Option Exercise6.891,50010,33517,311Sep 02 06:34 PM
Wiezorek JeffreySVP Clinical DevelopmentSep 01Sale58.241,50087,36215,811Sep 02 06:34 PM
BUTITTA CYNTHIA MChief Operating OfficerAug 25Option Exercise1.3510,00013,500105,477Aug 26 06:38 PM
BUTITTA CYNTHIA MChief Operating OfficerAug 25Sale58.2810,000582,77595,477Aug 26 06:38 PM
Kim Helen SusanEVP, Business DevelopmentAug 15Option Exercise51.432,400123,43211,400Aug 16 08:16 PM
Kim Helen SusanEVP, Business DevelopmentAug 15Sale63.012,400151,2299,000Aug 16 08:16 PM
Kim Helen SusanEVP, Business DevelopmentAug 12Option Exercise51.4333,5001,722,90542,500Aug 16 08:16 PM
Kim Helen SusanEVP, Business DevelopmentAug 12Sale60.0833,5002,012,5969,000Aug 16 08:16 PM
Wiezorek JeffreySVP Clinical DevelopmentAug 01Option Exercise6.891,50010,33516,367Aug 02 06:51 PM
Wiezorek JeffreySVP Clinical DevelopmentAug 01Sale56.901,50085,34314,867Aug 02 06:51 PM
BUTITTA CYNTHIA MChief Operating OfficerJul 25Option Exercise1.3510,00013,500105,401Jul 26 07:03 PM
BUTITTA CYNTHIA MChief Operating OfficerJul 25Sale50.9410,000509,35095,401Jul 26 07:03 PM
Wiezorek JeffreySVP Clinical DevelopmentJul 01Option Exercise6.891,50010,33516,367Jul 05 06:27 PM
Wiezorek JeffreySVP Clinical DevelopmentJul 01Sale50.001,50075,00714,867Jul 05 06:27 PM
BUTITTA CYNTHIA MChief Operating OfficerJun 27Option Exercise1.3510,00013,500105,401Jun 27 07:08 PM
BUTITTA CYNTHIA MChief Operating OfficerJun 27Sale50.1510,000501,48495,401Jun 27 07:08 PM
BUTITTA CYNTHIA MChief Operating OfficerJun 23Option Exercise1.3510,00013,500105,401Jun 27 07:08 PM
BUTITTA CYNTHIA MChief Operating OfficerJun 23Sale51.2810,000512,75495,401Jun 27 07:08 PM
DOUMANI ROYDirectorJun 06Sale58.384,000233,51627,865Jun 08 07:27 PM
DOUMANI ROYDirectorJun 06Sale57.9110,000579,065131,017Jun 08 07:27 PM
Wiezorek JeffreySVP Clinical DevelopmentJun 01Option Exercise6.891,50010,33516,367Jun 02 05:15 PM
Wiezorek JeffreySVP Clinical DevelopmentJun 01Sale51.301,50076,94914,867Jun 02 05:15 PM
Wiezorek JeffreySVP Clinical DevelopmentMay 31Option Exercise6.891,50010,33516,367Jun 02 05:15 PM
Wiezorek JeffreySVP Clinical DevelopmentMay 31Sale50.001,50075,00014,867Jun 02 05:15 PM